论文部分内容阅读
近年来,免疫学家们越来越多地考虑将细胞因子这一免疫激素应用于临床,以期通过调节免疫反应而达到治疗之目的。基于细胞因子的治疗已应用于相当一些疾病之中,包括寄生虫感染、结核病、肿瘤和艾滋病。然而,系统给予患者细胞因子存在着相当的局限性,包括毒性反应、短半衰期以及难以达到免疫有效部位等等。特别是外源性细胞因子引起的毒性副作用业已在一定程度上影响了其在肿瘤和艾滋病治疗中的应用。 人们正在积极寻找新的途径来克服使用外源性细胞因子的不足之处。近期英国《自然》周刊报导了英国著名的Wellcome医药公司的研究者们采取西夫氏硷形成分子(Schiff—base—forming molecules)去影响机体内源性细胞因子的产生,从而达到治疗及控制疾病的目的,同时避免了直接使用细胞因子而引起的不良副作用。
In recent years, immunologists are increasingly considering the application of cytokines, an immune hormone, to the clinic in order to achieve the goal of treatment by modulating the immune response. Cytokine-based therapies have been applied to quite a few diseases, including parasitic infections, tuberculosis, cancer and AIDS. However, there are considerable limitations to the systemic administration of cytokines in patients, including toxic reactions, short half-lives and difficulties in achieving immunocompetent sites. In particular, the toxic side effects caused by exogenous cytokines have already affected its application in the treatment of cancer and AIDS to a certain extent. People are actively looking for new ways to overcome the disadvantages of using exogenous cytokines. Recently, the “Nature” magazine in the UK reported that researchers from the well-known Wellcome Pharmaceutical Company in Britain have taken Schiff-base-forming molecules to influence the production of endogenous cytokines in the body so as to achieve the goal of treating and controlling diseases While avoiding the adverse side effects caused by the direct use of cytokines.